Accepted Manuscript

Treatment of brain disease in the mucopolysaccharidoses

Maurizio Scarpa, Paul J. Orchard, Angela Schulz, Patricia I. Dickson, Mark E. Haskins, Maria L. Escolar, Roberto Giugliani

PII: S1096-7192(17)30528-0

DOI: doi:10.1016/j.ymgme.2017.10.007


Reference: YMGME 6258

To appear in: Molecular Genetics and Metabolism

Received date: 18 August 2017 Revised date: 13 October 2017 Accepted date: 13 October 2017

Please cite this article as: Maurizio Scarpa, Paul J. Orchard, Angela Schulz, Patricia I. Dickson, Mark E. Haskins, Maria L. Escolar, Roberto Giugliani, Treatment of brain disease in the mucopolysaccharidoses. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Ymgme(2017), doi:10.1016/j.ymgme.2017.10.007

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

Supplement MPS and the brain

Treatment of brain disease in MPS

Treatment of brain disease in the mucopolysaccharidoses

Maurizio Scarpa^{a,*}, Paul J. Orchard^b, Angela Schulz^c, Patricia I. Dickson^d, Mark E. Haskins^e,

Maria L. Escolar^f, Roberto Giugliani^g

^aDepartment of Paediatric and Adolescent Medicine, Helios Dr. Horst Schmidt Kliniken, Center for Rare Diseases, Wiesbaden, Germany and Department for Womand and Child Health, University of Padova, Padova, Italy;

^bDepartment of Pediatrics, Division of Pediatric Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN, USA;

^cDepartment of Pediatrics, Children's Hospital, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;

^dDepartment of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA;

^eDepartments of Pathobiology and Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA;

^fDepartment of Pediatrics, Program for Neurodevelopment in Rare Disorders, Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA;

^gDepartment of Genetics, UFRGS & Medical Genetics Service, HCPA, and INAGEMP, Porto Alegre, RS, Brazil.

* Corresponding author:

Maurizio Scarpa

Department of Paediatric and Adolescent Medicine

Helios Dr. Horst Schmidt Kliniken, Center for Rare Diseases

Ludwig-Erhard-Strasse 100

65199 Wiesbaden, Germany

Tel: +49 611432314

Fax: +49 611433197

Email: Maurizio.Scarpa@helios-kliniken.de

AAV: adeno-associated viruses, AE: adverse event, BBB: blood-brain barrier, CLN2: ceroid lipofuscinosis neuronal type 2, CNS: central nervous system, CSF: cerebrospinal fluid, DQ: developmental quotient, ERT: enzyme replacement therapy, g7: 7-aminoacid glycopeptide, GAG: glycosaminoglycans, HSCT: hematopoietic stem cell transplantation, ICV: intracerebroventricular, IDDD: IT drug delivery device, IQ: intelligence quotient, IT: intrathecal, LAMP-1: lysosomal-associated membrane-1, MPS: mucopolysaccharidosis, MRI: magnetic resonance imaging, SCC: spinal cord compression, SGSH: N-sulfoglucosamine sulfohydrolase, SRT: substrate reduction therapy, SUMF: sulfatase modifying factor

Download English Version:

https://daneshyari.com/en/article/8343710

Download Persian Version:

https://daneshyari.com/article/8343710

<u>Daneshyari.com</u>